Vol 14, No 2 (2018)
Guidelines / Expert consensus
Published online: 2018-04-26
Chemotherapy- and radiotherapy-induced nausea and vomiting
DOI: 10.5603/OCP.2018.0010
Oncol Clin Pract 2018;14(2):53-61.
Abstract
Not available
References
- Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol. 2008; 5(1): 32–43.
- Basch E, Prestrud AA, Hesketh P, et al. Antiemetics: American Society of ical ogy ical Practice Guideline Update. J Clin Oncol. 2011; 29: 4189–4198.
- Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--state of the art. Support Care Cancer. 2011; 19 Suppl 1: S43–S47.
- Roila F, Molassiotis A, Herrstedt J, et al. participants of the MASCC/ESMO Consensus Conference Copenhagen 2015. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5): v119–v133.
- Hesketh PJ, Bohlke K, Lyman GH, et al. American Society of Clinical Oncology. Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2016; 34(4): 381–386.
- Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017; 28(6): 1260–1267.
- Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007; 15(9): 1023–1033.
- Billio A, Morello E, Clarke MJ. Serotonin receptor antagonists for highly emetogenic chemotherapy in adults. Cochrane Database Syst Rev. 2010(1): CD006272.
- Botrel TE, Clark OA, Clark L, et al. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011; 19(6): 823–832.
- dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012; 104(17): 1280–1292.
- Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol. 2015; 26(6): 1081–1090.
- Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 375(2): 134–142.
- Ruhlmann CH, Jahn F, Jordan K, et al. MASCC/ESMO. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines. Support Care Cancer. 2005; 13(2): 122–128.